The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)
Phase 3
- Conditions
- Breast cancer
- Registration Number
- JPRN-jRCT1080220048
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with Stage I, II or IIIA breast cancer positive for axillary lymph node metastasis
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy and safety
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of UFT + TAM versus CMF + TAM in adjuvant breast cancer therapy by Taiho Pharmaceutical?
How does the efficacy of UFT + TAM compare to CMF + TAM in phase III adjuvant breast cancer trials (JPRN-jRCT1080220048)?
Which biomarkers predict response to UFT + TAM or CMF + TAM in hormone receptor-positive breast cancer adjuvant therapy?
What are the adverse event profiles and management strategies for UFT + TAM versus CMF + TAM in breast cancer adjuvant therapy?
How do UFT + TAM and CMF + TAM compare to other fluoropyrimidine-based regimens in breast cancer treatment landscapes?